
    
      This trial is a single-center, prospective phase II clinical study, which mainly evaluates
      the efficacy and safety of first-line treatment with pembrolizumab in patients with recurrent
      and/or metastatic head and neck squamous cell carcinoma with PDL1 CPSâ‰¥20 in China.
    
  